Armistice Capital’s Bicycle Therapeutics BCYC Stock Holding History

Armistice Capital’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.8M	Buy	3,398,000 +162,000	+5%	+$926K	0.28%	67
2025 Q4	$22.9M	Buy	3,236,000 +258,000	+9%	+$1.9M	0.27%	61
2025 Q3	$23M	Buy	2,978,000 +178,000	+6%	+$1.34M	0.34%	45
2025 Q2	$19.5M	Buy	2,800,000 +128,000	+5%	+$1.02M	0.34%	48
2025 Q1	$22.7M	Buy	2,672,000 +476,000	+22%	+$5.61M	0.34%	59
2024 Q4	$30.7M	Buy	2,196,000 +240,000	+12%	+$5.14M	0.42%	45
2024 Q3	$44.3M	Sell	1,956,000 -16,000	-0.8%	-$369K	0.71%	28
2024 Q2	$39.9M	Buy	1,972,000 +300,000	+18%	+$6.78M	0.5%	34
2024 Q1	$41.6M	Buy	1,672,000 +136,000	+9%	+$2.89M	0.55%	33
2023 Q4	$27.8M	Buy	1,536,000 +536,000	+54%	+$8.87M	0.38%	48
2023 Q3	$20.1M	Buy	1,000,000 +124,000	+14%	+$2.84M	0.31%	58
2023 Q2	$22.4M	Buy	876,000 +140,000	+19%	+$3.25M	0.32%	58
2023 Q1	$15.7M	Buy	+736,000	New	+$18.5M	0.23%	74

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

GSK plc London $599M AUM

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital's BCYC Position: Q1 2026 in Review

Armistice Capital increased its Bicycle Therapeutics (BCYC) stake by 5% in Q1 2026, buying an estimated $926K and bringing the position to 3,398,000 shares worth $15.8M. The position accounts for 0.28% of the portfolio, ranked #67.

Armistice Capital first reported a position in BCYC in Q1 2023 and has held it in 13 quarters since. The position peaked at $44.3M in Q3 2024. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

Armistice Capital held 3,398,000 shares of Bicycle Therapeutics worth $15.8M as of Q1 2026.
Armistice Capital bought 162,000 Bicycle Therapeutics shares in Q1 2026, an estimated $926K.
Bicycle Therapeutics made up 0.28% of Armistice Capital's portfolio in Q1 2026, its #67 holding.
Armistice Capital first reported a position in Bicycle Therapeutics in Q1 2023 and has held it in 13 quarters since.
Armistice Capital's Bicycle Therapeutics position peaked at $44.3M in Q3 2024.
98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.